A blueprint for DNA vaccine design. (Contributo in volume (capitolo o saggio))

Type
Label
  • A blueprint for DNA vaccine design. (Contributo in volume (capitolo o saggio)) (literal)
Anno
  • 2014-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1007/978-1-4939-0410-5_1 (literal)
Alternative label
  • Iurescia, Sandra; Fioretti, Daniela; Rinaldi, Monica (2014)
    A blueprint for DNA vaccine design.
    in DNA vaccines Methods and Protocols Third Edition, 2014
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Iurescia, Sandra; Fioretti, Daniela; Rinaldi, Monica (literal)
Pagina inizio
  • 3 (literal)
Pagina fine
  • 10 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#titoloVolume
  • DNA vaccines Methods and Protocols Third Edition (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#volumeInCollana
  • 1143 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
  • 8 (literal)
Note
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • Institute of Translational Pharmacology (IFT), National Research Council (CNR), via Fosso del Cavaliere 100, 00133, Rome, Italy. (literal)
Titolo
  • A blueprint for DNA vaccine design. (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#curatoriVolume
  • Rinaldi, Monica; Fioretti, Daniela; Iurescia, Sandra (literal)
Abstract
  • Although safety concerns have been overcome, lower immunogenicity profiles of DNA vaccines have hindered their progress in humans. DNA vaccines need to make up for this limitation by altering plasmid construction through vector design innovations intended for enhancement of transgene expression and immunogenicity. The next-generation vectors also address safety issues such as selection markers. This chapter discusses (a) plasmid backbone design, (b) enhancement of antigenic protein expression and immunogenicity, and (c) vector modification to increase innate immunity. Modifications of the basic design, when combined with improved delivery devices and/or prime/boost regimens, may enhance DNA vaccine performance and clinical outcomes. (literal)
Prodotto di
Autore CNR

Incoming links:


Autore CNR di
Prodotto
data.CNR.it